Data investigation

GLP-1 & Weight Loss Care Access by State (2026)

State-by-state dataset of GLP-1 and medical weight-loss care access: 31,083 NPI-verified obesity-medicine, endocrinology, and bariatric clinics, clinics per 100,000 residents, verified telehealth coverage, the cheapest verified compounded semaglutide and tirzepatide price in every state, and a Care Gap Index comparing each state's adult obesity prevalence (CDC BRFSS 2024) to its specialist supply.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
9 min read·3 citations

This access report is part of Weight Loss Rankings' living editorial database. It joins three verifiable sources — the CMS NPPES provider registry, US Census population estimates, and our own verified GLP-1 telehealth provider dataset — into one state-by-state table you can download, cite, and re-derive.

Where you live still determines how easy it is to see a weight-loss clinician in person. We filtered the CMS National Provider registry to every active clinic and practitioner with an obesity-medicine, endocrinology, bariatric, or weight-management-adjacent taxonomy — 31,083 NPI-verified records across all 50 states and DC — and divided each state's count by its Census population estimate.[1] The result: Maryland has 18.15 relevant clinics per 100,000 residents, while Iowa has just 5.24 — a 3.5× gap between the best- and worst-served states.

The second half of the story is that the gap matters less than it used to. Our verified telehealth dataset counts 119 GLP-1 telehealth providers with published pricing, 70 of which serve all 50 states — so every state, including the thinnest in-person markets, has at least 75 verified telehealth options. The full methodology, including exactly what this dataset does not claim, is below the table.

The headline numbers

31,083

NPI-verified clinics

50 states + DC, CMS NPPES

3.5×

in-person access gap

Maryland 18.15 vs Iowa 5.24 per 100k

119

telehealth providers

70 serve all 50 states

$65–79

cheapest sema /mo

lowest verified ongoing compounded price, by state

The full state table

One row per state, plus Washington, D.C. “Clinics” counts every active, NPI-verified practice relevant to medical weight management; “specialist-primary” is the subset whose primary NPPES specialty is obesity medicine, endocrinology, or bariatric practice. “Telehealth providers” and the cheapest verified compounded prices reflect only providers that publish which states they serve. “Adult obesity %” is the CDC BRFSS 2024 prevalence estimate for adults 18+, and the Care Gap Index compares that burden to the state's clinic supply — it gets its own section below the table. Click any state name to browse that state's clinic directory, or download the full table at the bottom of this page.

StateClinicsClinics / 100kSpecialist-primaryTelehealth providersCheapest sema /moCheapest tirz /moAdult obesity %Care Gap Index
Alabama4228.1811889$79$9738.9%1.18
Alaska7910.671985$79$10434.0%0.79
Arizona7259.56222102$65$9733.3%0.87
Arkansas2227.197487$79$10438.9%1.34
California3,4308.701,43098$66$9729.1%0.83
Colorado68411.48195103$66$9725.0%0.54
Connecticut44212.0324297$79$9732.0%0.66
Delaware12411.794395$79$9736.6%0.77
District of Columbia11716.666575$65$10425.5%0.38
Florida2,49510.68931104$65$9729.6%0.69
Georgia9768.7330598$65$9735.4%1.01
Hawaii825.673491$79$9727.0%1.18
Idaho1618.043396$79$10432.7%1.01
Illinois1,0938.60520101$79$9734.2%0.99
Indiana5237.55213100$79$9738.4%1.26
Iowa1705.24 (lowest)53100$79$9736.6%1.74
Kansas2548.557996$65$10437.6%1.09
Kentucky4519.8313697$79$9737.2%0.94
Louisiana3918.5013688$79$9739.2%1.15
Maine946.693697$79$9733.2%1.23
Maryland1,13718.15 (highest)44597$79$9732.7%0.45
Massachusetts84511.8455794$79$9727.0%0.57
Michigan9919.7734599$66$9736.1%0.92
Minnesota3045.2520798$79$9732.3%1.53
Mississippi2307.828578$79$10440.4%1.28
Missouri5158.2524697$79$9734.6%1.04
Montana948.272796$79$9731.0%0.93
Nebraska1165.784997$79$9737.6%1.62
Nevada2778.4810497$79$9734.2%1.00
New Hampshire1309.237597$79$9731.1%0.84
New Jersey1,17012.3154793$79$10427.7%0.56
New Mexico1547.235295$65$10434.5%1.19
New York2,19311.041,157100$66$10429.5%0.66
North Carolina1,0669.6537999$79$9734.5%0.89
North Dakota465.772192$79$9736.8%1.59
Ohio9588.0642298$79$9736.9%1.14
Oklahoma3358.1899100$65$9736.8%1.12
Oregon2646.1812596$79$9733.5%1.35
Pennsylvania1,46211.18614101$79$9734.2%0.76
Rhode Island1029.174693$79$10431.1%0.84
South Carolina5119.3316491$79$9734.6%0.92
South Dakota677.253094$79$10437.0%1.27
Tennessee5016.9317997$79$97
Texas2,4787.92939105$66$9735.6%1.12
Utah2186.2265101$65$9731.0%1.24
Vermont446.782095$79$10429.0%1.06
Virginia7949.01333100$65$10432.3%0.89
Washington5176.50248101$65$9731.5%1.20
West Virginia21312.037491$79$10441.4%0.86
Wisconsin3596.0219296$79$10437.4%1.54
Wyoming579.70697$79$9732.5%0.83

Highlighted rows mark the highest (Maryland) and lowest (Iowa) clinics-per-100k jurisdictions. CDC did not publish a 2024 obesity estimate for Tennessee, so its obesity and Care Gap cells show an em dash. Snapshot: July 2026. The same rows are downloadable as CSV/JSON in the “Cite this data” section below.

Access deserts and best-served states

Thinnest in-person access (clinics per 100k)

  1. 1.Iowa5.24/100k · 100 telehealth
  2. 2.Minnesota5.25/100k · 98 telehealth
  3. 3.Hawaii5.67/100k · 91 telehealth
  4. 4.North Dakota5.77/100k · 92 telehealth
  5. 5.Nebraska5.78/100k · 97 telehealth

Densest in-person access (clinics per 100k)

  1. 1.Maryland18.15/100k · 97 telehealth
  2. 2.District of Columbia16.66/100k · 75 telehealth
  3. 3.New Jersey12.31/100k · 93 telehealth
  4. 4.Connecticut12.03/100k · 97 telehealth
  5. 5.West Virginia12.03/100k · 91 telehealth

The thin end of the table is dominated by the Upper Midwest and the islands: Iowa, Minnesota, Hawaii, North Dakota, Nebraska all sit at or below 5.78 clinics per 100,000 residents. These are large-area, lower-population states where specialist care concentrates in one or two metro systems — an honest reading is “fewer specialist doors to knock on,” not “no care at all,” since primary-care prescribing isn't captured here (see methodology).

At the dense end, Maryland, District of Columbia, New Jersey, Connecticut, West Virginia lead the country. The corridor around Maryland and DC benefits from an unusual concentration of academic medical centers and endocrinology practices relative to population; compact high-income states like New Jersey and Connecticut show the same pattern.

Set the two halves of this table side by side and a clear pattern emerges: telehealth coverage compensates almost exactly where in-person density is thinnest. Every state on the “deserts” list still has 75+ verified GLP-1 telehealth options — Iowa, last in clinics per capita, has 100 verified telehealth providers, more than many dense states — because 70 of the 119 verified providers serve all 50 states. For medication access specifically — compounded semaglutide and tirzepatide pricing — the state you live in now changes your options far less than it did before telehealth. Our state-by-state telehealth pages list which providers serve each state, and the state Medicaid GLP-1 checker covers the public-coverage side of the same question.

The Care Gap Index — where obesity burden outruns specialist supply

The Care Gap Index is the ratio of a state's adult obesity prevalence to its weight-loss clinics per 100,000 residents, each measured against the national median — 1.00 means burden and supply are balanced, and anything above 1.00 means the state carries more obesity burden than specialist supply. By that measure, Iowa is the most under-supplied state in the country at 1.74: an adult obesity rate of 36.6% served by just 5.24 relevant clinics per 100,000 residents.

Largest care gaps (index)

  1. 1.Iowa1.7436.6% obesity · 5.24/100k
  2. 2.Nebraska1.6237.6% obesity · 5.78/100k
  3. 3.North Dakota1.5936.8% obesity · 5.77/100k
  4. 4.Wisconsin1.5437.4% obesity · 6.02/100k
  5. 5.Minnesota1.5332.3% obesity · 5.25/100k

Best-supplied relative to burden (index)

  1. 1.District of Columbia0.3825.5% obesity · 16.66/100k
  2. 2.Maryland0.4532.7% obesity · 18.15/100k
  3. 3.Colorado0.5425.0% obesity · 11.48/100k
  4. 4.New Jersey0.5627.7% obesity · 12.31/100k
  5. 5.Massachusetts0.5727.0% obesity · 11.84/100k

The pattern is starkly regional: the Upper Midwest — Iowa, Nebraska, North Dakota, Wisconsin, Minnesota — fills the entire worst-five list, pairing above-median obesity rates with some of the thinnest specialist coverage in the country. The best-supplied end is the inverse: District of Columbia (0.38), Maryland (0.45), Colorado (0.54) combine dense clinic networks with below-median obesity prevalence. The index measures specialist in-person density, not overall access — primary-care prescribing isn't counted, and telehealth fills part of the gap: every state on the largest-gaps list still has 92+ verified GLP-1 telehealth options.

Cite this data July 2026

Free to cite with a link

Original state-by-state analysis joining the CMS NPPES registry, US Census population estimates, and our verified GLP-1 telehealth provider dataset. Figures update automatically when the snapshot regenerates.

31,083
NPI-verified weight-loss clinics (50 states + DC)
3.5×
access gap — Maryland vs Iowa, clinics per 100k
119
verified GLP-1 telehealth providers nationwide
$65–79
cheapest verified compounded semaglutide /mo, by state

Key findings (copy to cite)

  • The US has 31,083 NPI-verified in-person clinics relevant to medical weight-loss care — obesity medicine, endocrinology, and bariatric practices — across all 50 states and DC as of July 2026, per the CMS NPPES registry. 12,736 of them list a weight-management specialty as their PRIMARY taxonomy. (Source: Weight Loss Rankings GLP-1 Care Access by State dataset, https://www.weightlossrankings.org/research/glp1-care-access-by-state, July 2026)
  • Maryland has the densest in-person weight-loss care access in the country at 18.15 relevant clinics per 100,000 residents; Iowa has the thinnest at 5.24 — a 3.5× access gap between the best- and worst-served states. (Source: Weight Loss Rankings GLP-1 Care Access by State dataset, https://www.weightlossrankings.org/research/glp1-care-access-by-state, July 2026)
  • 119 verified GLP-1 telehealth providers with published pricing operate in the US as of July 2026, and 70 of them serve all 50 states. Every state (and DC) has at least 75 verified telehealth options. (Source: Weight Loss Rankings GLP-1 Care Access by State dataset, https://www.weightlossrankings.org/research/glp1-care-access-by-state, July 2026)
  • The cheapest verified ongoing compounded semaglutide price ranges from $65 to $79 per month depending on the state; for compounded tirzepatide the state-by-state floor is $97 to $104 per month. (Source: Weight Loss Rankings GLP-1 Care Access by State dataset, https://www.weightlossrankings.org/research/glp1-care-access-by-state, July 2026)
  • The five best-served states by in-person clinics per capita are Maryland (18.15), District of Columbia (16.66), New Jersey (12.31), Connecticut (12.03), West Virginia (12.03); the five thinnest are Iowa (5.24), Minnesota (5.25), Hawaii (5.67), North Dakota (5.77), Nebraska (5.78) — all per 100,000 residents. (Source: Weight Loss Rankings GLP-1 Care Access by State dataset, https://www.weightlossrankings.org/research/glp1-care-access-by-state, July 2026)
  • Iowa has the largest gap between obesity burden and specialist supply of any US state as of July 2026: a Care Gap Index of 1.74, with an adult obesity prevalence of 36.6% (CDC BRFSS 2024) against just 5.24 weight-loss clinics per 100,000 residents. (Source: Weight Loss Rankings GLP-1 Care Access by State dataset, https://www.weightlossrankings.org/research/glp1-care-access-by-state, July 2026)

Statistical notes

  • Clinic counts are NPI-verified records from the CMS NPPES bulk registry, filtered by a taxonomy allow-list (obesity medicine, endocrinology, bariatric, weight-management-adjacent); mismatched secondary-tier records are excluded.
  • Telehealth counts include only GLP-1 telehealth providers with at least one verified ongoing compounded monthly price AND published state coverage — providers without published coverage are excluded, so counts are floors, not ceilings.
  • Clinics per 100k uses US Census Bureau NST-EST2024 state population estimates (POPESTIMATE2024) as the denominator.
  • This dataset contains no insurance-acceptance data and no self-reported telehealth flags — registry-verified and price-verified fields only.

Free for editorial use. Please credit Weight Loss Rankings with a link to weightlossrankings.org/research/glp1-care-access-by-state.

Methodology

Every number on this page comes from one of four public sources:

  1. In-person clinics: CMS NPPES bulk registry, filtered to obesity-medicine, endocrinology, bariatric, and weight-management-adjacent taxonomies (relevant tiers only; secondary-tier mismatches excluded).[1] Each record is an active NPI. We report the total alongside the specialist-primary subset (12,736 of 31,083 records nationally) so that facility and adjacent-generalist records are never conflated with dedicated specialist practices.
  2. Telehealth coverage and prices: WeightLossRankings.org verified provider dataset — GLP-1 telehealth providers with at least one verified ongoing compounded monthly price and published state coverage. A provider counts toward a state only when its published coverage includes that state; the cheapest verified semaglutide/tirzepatide columns are the lowest verified ongoing monthly price among providers serving that state.
  3. Population denominators: US Census Bureau NST-EST2024 state population estimates (POPESTIMATE2024).[2]
  4. Adult obesity prevalence: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2024 — percent of adults aged 18+ with obesity, total stratification, via data.cdc.gov.[3]

The Care Gap Index is (state adult obesity prevalence ÷ national-median prevalence) ÷ (state clinics per 100,000 ÷ national-median clinics per 100,000). A value of 1.00 means a state's obesity burden matches its specialist supply; above 1.00, burden outruns supply. Tennessee has no published 2024 BRFSS estimate, so it carries no prevalence value and no index.

What we do not claim. This dataset contains no insurance-acceptance data — an NPI record tells you a clinic exists and what it practices, not whether it takes your plan. It contains no self-reported telehealth flags: NPPES telehealth fields are voluntary and inconsistently maintained, so we ignore them entirely and count telehealth only from our own verified provider dataset. And it does not capture GLP-1 prescribing by general primary-care physicians outside the taxonomy allow-list, so it measures specialist in-person access, not every possible prescriber. Only registry-verified and price-verified fields appear in the table.

Explore the data further

Frequently Asked Questions

References

  1. 1.Centers for Medicare & Medicaid Services. National Plan and Provider Enumeration System (NPPES) — NPI Registry Bulk Data Dissemination. CMS NPPES. 2026. https://download.cms.gov/nppes/NPI_Files.html
  2. 2.U.S. Census Bureau. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico (NST-EST2024). US Census Bureau Population Estimates Program. 2024. https://www.census.gov/data/tables/time-series/demo/popest/2020s-state-total.html
  3. 3.Centers for Disease Control and Prevention. Nutrition, Physical Activity, and Obesity — Behavioral Risk Factor Surveillance System: percent of adults aged 18 and older who have obesity, 2024. CDC BRFSS via data.cdc.gov (dataset hn4x-zwk7). 2024. https://data.cdc.gov/d/hn4x-zwk7

Medicaid GLP-1 Spending by State (2019–2026)

Quarterly tracker of Medicaid GLP-1 spending and prescriptions in every state, from the CMS State Drug Utilization Data. US Medicaid spent about $8.8 billion (gross, before rebates) on GLP-1s in 2024; Wegovy's national spend rose from $1.43 billion in 2024 to $2.60 billion in 2025 and Zepbound's jumped 6.3×. When Pennsylvania ended obesity-drug coverage on January 1, 2026, quarterly Wegovy prescriptions fell 96%. Full downloadable dataset inside.

10 min read

FDA Warning Letters to Compounded GLP-1 Telehealth Providers: The Live Investigation

Every FDA warning letter we have identified that targets a compounded GLP-1 telehealth provider, compounding pharmacy, or related weight-loss business — with violation patterns, issuing offices, and what is actually being cited. Live dataset, updated bi-weekly via automated FDA scraper.

10 min read

GLP-1 Compounded Pricing Index 2026

What telehealth providers actually charge for compounded semaglutide and tirzepatide — the median, the cheapest and priciest, and the gap to brand-name Wegovy — across the 350+ GLP-1 providers with verified pricing.

9 min read

GLP-1 Insurance Coverage at the 10 Largest US Insurers: A 2026 Audit

Does your insurance cover Wegovy or Zepbound? We audited the 10 largest US health insurers — covering more than 460 million members combined — and the answer is the same everywhere: technically yes, but every plan requires prior authorization and coverage is plan-specific.

9 min read

How Compounded GLP-1 Prices Moved Over the Last 16 Months: Provider-by-Provider Trajectories

We tracked monthly cash prices for compounded semaglutide across the largest telehealth providers from January 2025 onward. Every provider in our tracked set has cut prices — but at very different rates, with the biggest movers converging on a $199 floor.

10 min read

Is $99 Compounded Semaglutide Real? We Verified Every Provider at the Floor Price

Multiple telehealth providers advertise compounded semaglutide at $99 per month — well below the market median. We verified the licensing, pharmacy partner, dose, and total monthly cost for each one.

9 min read

Where to get GLP-1: vetted providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.6

Maximus

Men seeking compounded GLP-1 alongside testosterone optimization

8.2

Enhance MD

Lab-monitored compounded GLP-1 with mandatory video visit

7.1

MEDVi

Patients who want the option to switch between compounded and brand-name GLP-1 through one provider